Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ominsky

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosisXiaodong Li, Michael S Ominsky, Kelly S Warmington, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 16, 2024
Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid studyFrancis H Glorieux, Bente Langdahl, Roland Chapurlat, et al.
Bone|May 30, 2006
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopeniaJi Li, Ildiko Sarosi, Russell C Cattley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 5, 2011
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bonesMichael S Ominsky, Chaoyang Li, Xiaodong Li, et al.
JAMA Pediatrics|November 17, 2025
Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical TrialRavi Savarirayan, Ciara McDonnell, Carlos A Bacino, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 14, 2008
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strengthXiaodong Li, Michael S Ominsky, Qing-Tian Niu, et al.
Advances in Therapy|May 1, 2024
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2010
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strengthMichael S Ominsky, Fay Vlasseros, Jacquelin Jolette, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2008
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKLPaul J Kostenuik, Hung Q Nguyen, James McCabe, et al.
Nature Communications|May 28, 2016
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repairMonica Florio, Kannan Gunasekaran, Marina Stolina, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosisXiaodong Li, Michael S Ominsky, Kelly S Warmington, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 16, 2024
Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid studyFrancis H Glorieux, Bente Langdahl, Roland Chapurlat, et al.
Bone|May 30, 2006
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopeniaJi Li, Ildiko Sarosi, Russell C Cattley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 5, 2011
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bonesMichael S Ominsky, Chaoyang Li, Xiaodong Li, et al.
JAMA Pediatrics|November 17, 2025
Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical TrialRavi Savarirayan, Ciara McDonnell, Carlos A Bacino, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 14, 2008
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strengthXiaodong Li, Michael S Ominsky, Qing-Tian Niu, et al.
Advances in Therapy|May 1, 2024
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2010
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strengthMichael S Ominsky, Fay Vlasseros, Jacquelin Jolette, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2008
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKLPaul J Kostenuik, Hung Q Nguyen, James McCabe, et al.
Nature Communications|May 28, 2016
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repairMonica Florio, Kannan Gunasekaran, Marina Stolina, et al.
Pageof 9